Multiple Sclerosis Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Multiple Sclerosis stocks.

Multiple Sclerosis Stocks Recent News

Date Stock Title
Oct 2 ALKS Alkermes (NASDAQ:ALKS) shareholder returns have been favorable, earning 62% in 5 years
Oct 1 SNY Update: Market Chatter: Sanofi Asks Bidders to Revise Offers for Consumer Health Unit
Oct 1 SNY Market Chatter: Sanofi Asks Bidders to Revise Offers for Consumer Health Unit
Oct 1 SNY Sanofi Is Said to Ask Bidders to Revise Consumer Health Offers
Oct 1 BWAY BrainsWay: More Cash, More Uncertainty
Oct 1 BWAY Brainsway (BWAY) Soars 14.5%: Is Further Upside Left in the Stock?
Sep 30 SNY Sanofi, Regeneron's Dupixent Gets FDA Approval for COPD
Sep 30 CTNM IPO Roundup: FrontView REIT, StandardAero and more
Sep 30 BWAY BrainsWay Announces US$20 Million Private Placement with Valor Equity Partners
Sep 28 SNY Regeneron, Sanofi announce Dupixent approval in China for patients with COPD
Sep 27 SNY Regeneron-Sanofi Drug Wins FDA Approval To Treat COPD
Sep 27 ZBIO Biotech IPOs return as sector recovers after funding overhang
Sep 27 SNY Regeneron/ Sanofi granted FDA label expansion for Dupixent in COPD
Sep 27 SNY Sanofi/Regeneron’s Dupixent set to dominate COPD biologics market following FDA approval
Sep 27 SNY Regeneron, Sanofi Get FDA OK for Dupixent to Treat COPD
Sep 27 SNY Sanofi, Regeneron get additional Chinese approval for Dupixent
Sep 27 SNY Regeneron And Sanofi Snag Their $6 Billion-Potential COPD Approval For Dupixent
Sep 27 SNY Press Release: Dupixent approved in the US as the first-ever biologic medicine for patients with COPD
Sep 27 SNY Dupixent® (dupilumab) Approved in the U.S. as the First-ever Biologic Medicine for Patients with COPD
Sep 27 SNY Press Release: Dupixent approved in China as the first-ever biologic medicine for patients with COPD
Multiple Sclerosis

Multiple sclerosis (MS) is a demyelinating disease in which the insulating covers of nerve cells in the brain and spinal cord are damaged. This damage disrupts the ability of parts of the nervous system to communicate, resulting in a range of signs and symptoms, including physical, mental, and sometimes psychiatric problems. Specific symptoms can include double vision, blindness in one eye, muscle weakness, trouble with sensation, or trouble with coordination. MS takes several forms, with new symptoms either occurring in isolated attacks (relapsing forms) or building up over time (progressive forms). Between attacks, symptoms may disappear completely; however, permanent neurological problems often remain, especially as the disease advances.While the cause is not clear, the underlying mechanism is thought to be either destruction by the immune system or failure of the myelin-producing cells. Proposed causes for this include genetics and environmental factors such as being triggered by a viral infection. MS is usually diagnosed based on the presenting signs and symptoms and the results of supporting medical tests.There is no known cure for multiple sclerosis. Treatments attempt to improve function after an attack and prevent new attacks. Medications used to treat MS, while modestly effective, can have side effects and be poorly tolerated. Physical therapy can help with people's ability to function. Many people pursue alternative treatments, despite a lack of evidence of benefit. The long-term outcome is difficult to predict, with good outcomes more often seen in women, those who develop the disease early in life, those with a relapsing course, and those who initially experienced few attacks. Life expectancy is on average 5 to 10 years lower than that of an unaffected population.Multiple sclerosis is the most common immune-mediated disorder affecting the central nervous system. In 2015, about 2.3 million people were affected globally with rates varying widely in different regions and among different populations. That year about 18,900 people died from MS, up from 12,000 in 1990. The disease usually begins between the ages of 20 and 50 and is twice as common in women as in men. MS was first described in 1868 by Jean-Martin Charcot. The name multiple sclerosis refers to the numerous scars (sclerae—better known as plaques or lesions) that develop on the white matter of the brain and spinal cord. A number of new treatments and diagnostic methods are under development.

Browse All Tags